Becton, Dickinson and Company (NYSE:BDX) Position Increased by Confluence Investment Management LLC

Confluence Investment Management LLC increased its stake in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 1.5% during the 2nd quarter, HoldingsChannel reports. The firm owned 73,567 shares of the medical instruments supplier’s stock after acquiring an additional 1,080 shares during the period. Confluence Investment Management LLC’s holdings in Becton, Dickinson and were worth $18,136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Somerset Trust Co raised its stake in Becton, Dickinson and by 0.3% during the 1st quarter. Somerset Trust Co now owns 14,459 shares of the medical instruments supplier’s stock valued at $3,846,000 after acquiring an additional 39 shares in the last quarter. First Citizens Bank & Trust Co. raised its stake in Becton, Dickinson and by 4.1% during the 4th quarter. First Citizens Bank & Trust Co. now owns 1,016 shares of the medical instruments supplier’s stock valued at $255,000 after acquiring an additional 40 shares in the last quarter. Blossom Wealth Management raised its stake in Becton, Dickinson and by 3.5% during the 1st quarter. Blossom Wealth Management now owns 1,192 shares of the medical instruments supplier’s stock valued at $317,000 after acquiring an additional 40 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its stake in Becton, Dickinson and by 1.1% during the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,805 shares of the medical instruments supplier’s stock valued at $1,012,000 after acquiring an additional 40 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC raised its stake in Becton, Dickinson and by 1.6% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 2,535 shares of the medical instruments supplier’s stock valued at $675,000 after acquiring an additional 41 shares in the last quarter. Institutional investors own 86.74% of the company’s stock.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. The Goldman Sachs Group lifted their target price on Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research note on Tuesday, August 16th. StockNews.com upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Saturday, September 10th. Stifel Nicolaus lowered their price target on Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. Wells Fargo & Company upgraded Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price target on the stock in a research report on Friday, June 24th. Finally, Morgan Stanley lowered their price target on Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and presently has a consensus rating of “Hold” and a consensus price target of $277.63.

Insider Activity

In other news, EVP Samrat S. Khichi sold 9,185 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the transaction, the executive vice president now owns 5,928 shares in the company, valued at $1,543,888.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Thomas E. Polen, Jr. sold 9,500 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the sale, the chief executive officer now owns 28,878 shares of the company’s stock, valued at $7,656,424.14. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Samrat S. Khichi sold 9,185 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total value of $2,392,141.40. Following the sale, the executive vice president now directly owns 5,928 shares of the company’s stock, valued at approximately $1,543,888.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,160 shares of company stock worth $5,036,751. 0.50% of the stock is owned by corporate insiders.

Becton, Dickinson and Stock Performance

Shares of NYSE BDX opened at $254.32 on Monday. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $72.53 billion, a price-to-earnings ratio of 43.85, a PEG ratio of 3.33 and a beta of 0.57. The stock’s fifty day simple moving average is $251.96 and its 200 day simple moving average is $254.68. Becton, Dickinson and Company has a 52-week low of $231.46 and a 52-week high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The business had revenue of $4.64 billion for the quarter, compared to analysts’ expectations of $4.47 billion. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The company’s quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.74 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 11.31 earnings per share for the current fiscal year.

Becton, Dickinson and Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be issued a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.37%. Becton, Dickinson and’s dividend payout ratio is 60.00%.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.